Very-long-chain acyl-CoA dehydrogenase (VLCAD) is one of four straight-chain acyl-CoA dehydrogenase (ACD) enzymes, which are all nuclear encoded mitochondrial flavoproteins catalyzing the initial step in fatty acid β-oxidation. We have used the very fast, Rapid Amplification of cDNA Ends (RACE) based strategy to obtain the sequence of cDNAs encoding human VLCAD from placenta and fibroblasts. Alignment of the predicted amino acid sequence of human VLCAD with those of the other human ACD enzymes revealed extensive sequence homology. Moreover, human VLCAD and human acyl-CoA oxidase showed extensive sequence homology corroborating the notion that these genes are evolutionarily related. Southern blot analysis of genomic DNA from hybrid cell lines was used to localize the VLCAD gene to human chromosome 17p11.2-p11.13105. Using Northern and Western blot analysis to investigate the tissue specific distribution of VLCAD mRNA and protein in several human tissues we showed that VLCAD is most abundant in heart and skeletal muscle. This agrees well with the fact that cardiac and muscle symptoms are characteristic for patients with VLCAD deficiency. Northern blot analysis and sequencing of cloned PCR amplified VLCAD cDNA from four unrelated patients with VLCAD deficiency showed that VLCAD mRNA was undetectable in one patient and that the other three have mutations in both VLCAD alleles. Western blot analysis of patient fibroblasts showed that the identified mutations result in severely reduced amounts of VLCAD protein. None of the patients harbored identical mutations suggesting that the mutational heterogeneity in VLCAD deficiency is large.
INTRODUCTION
Very-long-chain acyl-CoA dehydrogenase (VLCAD) (EC 1.3.99.13) is one of four straight-chain acyl-CoA dehydrogenases which catalyze the first dehydrogenation step in the β-oxidation of fatty acyl-CoA esters of different chain lengths in mitochondria (1, 2) .
All acyl-CoA dehydrogenase (ACD) enzymes, except VLCAD, are matrix located homotetrameric enzymes composed of monomers of nearly identical size. VLCAD is a membrane associated homodimer with monomers of larger size than the other enzymes (2, 3) . The ACD enzymes are all synthesized as precursor proteins with an amino terminal leader peptide which is cleaved off on import into mitochondria, producing the mature monomer. In mitochondria, the monomers are assembled to form the functional enzyme, with one molecule of flavin adenine dinucleotide (FAD) attached per subunit (3) (4) (5) . The homotetrameric ACD enzymes show extensive sequence homology (6) (7) (8) (9) (10) . Based on this, it has been suggested that the straight-chain ACD enzymes, i.e. medium-chain acyl-CoA dehydrogenase (MCAD), short-chain acyl-CoA dehydrogenase (SCAD) and long-chain *To whom correspondence should be addressed Downloaded from https://academic.oup.com/hmg/article-abstract/5/4/461/595037 by guest on 24 December 2018 acyl-CoA dehydrogenase (LCAD) together with the branchedchain ACD enzymes, i.e., isovaleryl-CoA dehydrogenase (IVD) and short/branched-chain-acyl-CoA dehydrogenase (SBCAD) constitute a gene family (11) .
Inherited defects in all four straight-chain ACD enzymes have been described (12) (13) (14) , with MCAD deficiency being the most commonly recognized. The clinical manifestations of the straight-chain acyl-CoA dehydrogenase deficiencies are diverse, but generally they occur intermittently, with a potentially fatal outcome at the initial presentation (14) . The clinical symptoms usually occur precipitously in periods of metabolic stress, which increase the energy demands of tissues such as the heart, liver, and skeletal muscle on fatty-acid β-oxidation (14) . All of these defects usually present in the first years of life (14) .
LCAD is active towards C 10 -C 18 acyl-CoA esters with peak activity towards C 12 -C 14 esters (15) . It has therefore been presumed that patients with decreased dehydrogenation of palmitoyl-CoA had defects in their LCAD enzyme (16) . However, molecular analysis of LCAD cDNA and protein have failed to establish such a correlation in the patients investigated so far (17, 18) . With the recent identification of the VLCAD enzyme (2) , which is active towards acyl-CoA esters of the same and longer chain length as LCAD, an explanation of this apparent inconsistency was made possible. In fact the VLCAD enzyme exhibits a 10-fold higher activity towards palmitoyl-CoA as a substrate than that of LCAD (2, 3) . Recently, enzyme activity measurements in cells from patients indicated to have a defect in the dehydrogenation of long-chain acyl-CoA esters, showed that the enzyme defect was localized to the mitochondrial membrane (13, 19) , strongly suggesting a defect in VLCAD. Moreover, investigation of VLCAD antigen in seven such patients, including some who were initially diagnosed as suffering from LCAD deficiency, showed that the defective dehydrogenation of palmitoyl-CoA could be ascribed to defects that caused the VLCAD protein to be unstable in all seven patients (3, 12, 18) . Very recently, while this manuscript was in preparation, Aoyama and coworkers reported the cloning of human VLCAD cDNA by a traditional cDNA library screening approach (20) . Moreover, they reported the identification of a single disease-causing mutation present in homozygous form in VLCAD cDNA from two patients (20) .
In the present study we report the use of a different and much faster, PCR-based approach to obtain the cDNA sequence of human VLCAD. Moreover, we report on the tissue specific distribution of VLCAD mRNA and protein in several human tissues and the chromosomal assignment of the human gene. Finally, we show that four unrelated patients with defective palmitoyl-CoA dehydrogenation have several different mutations in their VLCAD cDNA and only exhibit trace amounts of VLCAD protein in their cultured cells.
RESULTS

Characterization of human VLCAD cDNAs
We used information from the rat VLCAD cDNA sequence (21) to identify an expressed sequence tag (EST) from human fetal brain (accession no. T08506) in the EMBL/GeneBank databases, which most likely represented part of the human VLCAD cDNA. Employing this information, we designed primers to be used in a Rapid Amplification of cDNA Ends (RACE) based strategy aimed at identifying the human VLCAD cDNA sequence. 5′-RACE-PCR and 3′-RACE-PCR produced two overlapping fragments of approximately 900 bp and 1500 bp respectively with doublestranded adaptor ligated cDNA from both human placenta and fibroblasts as templates in parallel PCRs. The PCR products were cloned in a pCRII vector. Five clones harboring 5′-RACE-PCR products and three clones harboring 3′-RACE-PCR products were sequenced. In addition, the 5′ end and 3′ end PCR products were subjected to direct sequence analysis. Sequence analysis of all clones as well as direct sequence analysis of the corresponding PCR products showed identical sequence. Taken together the two fragments comprise a cDNA sequence of 2219 bp derived from four individual chromosomes (two from placenta from one individual and two from fibroblasts from another individual). Sequence comparison of our cDNA sequence with the cDNA sequence of rat VLCAD (21) showed that they share approximately 83% identical nucleotides and the two predicted protein sequences share approximately 85% identical amino acids. Therefore, the 2219 bp cDNA represents the human very-longchain acyl-CoA dehydrogenase (VLCAD) sequence. This is also evident when our cDNA sequence (accession no. X86556) is compared with the recently published human VLCAD cDNA (20) . Alignment of our VLCAD cDNA sequence with that of Aoyama and coworkers (20) revealed no nucleotide differences in the 5′-untranslated region and the coding region. However, the sequence of the 3′-untranslated region differed at position 2058-59 and in the segment from position 2112 to 2123, harboring the polyadenylation signal. Whether these differences are technically derived or represent true variants is not clear, but the fact that our cDNA sequence was obtained by direct sequencing of two individuals makes it very certain. Based on Kozak's criteria for an initiation codon, the ATG codon at position 1 is assigned to be the start codon (22) . The first in frame stop codon (TGA) is located at position 1966. Thus, our human VLCAD cDNA consists of a 85 bp long untranslated region in the 5′ end, a coding region of 1965 bp and a 3′ terminal untranslated region of 169 bp. A putative polyadenylation signal (AATAAA) (23) is located at position 2116-2121. The fact that we used a mix of 'lock-docking' primers for cDNA synthesis (see Materials and Methods) implies that the poly A tail must be located immediately following the 169 bp 3′ terminal untranslated region. Direct sequencing of the 3′ end fragments showed that human VLCAD cDNA had been primed with a 'lock-docking' primer with the 3′ terminal dinucleotide GA, indicating that the 168 bp 3′ end untranslated sequence is followed by the nucleotides TC and ends with a poly A tail. This is consistent with the sequence published by Aoyama and co-workers (20) .
Like rat VLCAD cDNA, the human cDNA is predicted to encode a precursor protein of 655 amino acids. Amino acid sequencing of the amino terminal peptide of rat and human VLCAD proteins showed that alanine at position 41 of the precursor protein is the first amino acid in the mature protein (20, 21) . Thus, the mature human VLCAD protein consists of 615 amino acids, and the amino terminal 40 residues of the precursor protein make up the leader peptide.
The nucleotide sequence data have been submitted to the EMBL Data Bank (accession no. X86556).
Tissue specific distribution
The tissue specific distribution of human VLCAD mRNA and protein was investigated by Northern and Western blot analysis. Northern blot analysis of mRNA from a variety of human tissues using a human VLCAD cDNA probe (Fig. 1) showed a 2.4 kb band in all tissues. In placenta, liver, skeletal muscle and pancreas an additional but weaker band of approximately 3 kb in length was also present. However, the 2.4 kb band corresponds well with the size expected from our and others (20) human VLCAD cDNA sequence and the size of rat VLCAD mRNA (21) . Furthermore, Western blot analysis of VLCAD protein from several human tissues (Fig. 2) only showed a single band (see below). Thus, the additional 3 kb band is most likely to have been caused by nonspecific hybridization of the VLCAD probe due to the very high GC content (close to 70%), as has previously been observed for other GC rich probes (9) . VLCAD mRNA is most abundant in heart and skeletal muscle, with drastically lower amounts observed in pancreas, liver, kidney and placenta. VLCAD mRNA was also detectable in lung and brain tissue, but in very low amounts.
Western blot analysis using a polyclonal antibody directed against the human VLCAD precursor protein showed a single band with an apparent molecular weight of approximately 66 kDa in several human tissues (Fig. 2) . The size of this band is in good agreement with the calculated size of 66 kDa and with the size of purified mature human VLCAD recently reported by Aoyama and co-workers (3). A similar tissue distribution as observed for VLCAD mRNA was observed with the largest amounts present in heart and skeletal muscle tissue. However, significant amounts of VLCAD protein were present in liver, whereas VLCAD mRNA did not seem to be particularly abundant in liver. This discrepancy is not due to degradation of the liver mRNA, as liver mRNA showed a band of similar intensity as the mRNAs from the other tissues when the integrity of the blots was checked for by hybridization with a β-actin probe (not shown). The expression of VLCAD in several rat tissues has been shown to be highly regulated on metabolic stress, in particular in liver (21) . Thus, a possible explanation for our results could be that β-oxidation was down-regulated in the liver samples from which the mRNAs were extracted and not in the samples used for protein extractions. Although this needs further investigation we believe that there can be no doubt that the liver is also an important site of action for the VLCAD enzyme.
Given the overlapping substrate specificities of VLCAD and LCAD, a possible explanation for the biochemical role of LCAD is that it plays a role in other tissues than VLCAD. We therefore decided to compare the tissue specific distribution of mRNA and protein for the two enzymes. Interestingly, the tissue specific distribution of LCAD mRNA ( Fig. 1 ) and protein ( Fig. 2 ) exhibited important differences to VLCAD. The most interesting differences were the observations that only low amounts of LCAD were present in heart tissue, and that LCAD was highly abundant in kidney. Similar to VLCAD, LCAD mRNA was most abundant in skeletal muscle, but there was no protein detectable in skeletal muscle. Examination of the Western blot membrane after staining for total protein (Ponceau staining) showed very large amounts of an unknown protein in the 40-45 kDa region from skeletal muscle. We believe that the enormous amounts of this protein may mask the LCAD antigen in skeletal muscle, thus explaining the lack of signal. In favor of this hypothesis is the observation that the same discrepancy between mRNA and protein amounts in skeletal muscle was observed for MCAD, which has nearly the same monomer size as LCAD.
We also compared the tissue specific distribution of VLCAD and LCAD mRNA and protein with that of MCAD. Interestingly, the results obtained with the MCAD probe and antibody were similar to those of VLCAD, the only difference being the complete lack of MCAD antigen in skeletal muscle, which is probably due to masking of MCAD antigen as discussed above.
Finally, it should be emphasized that the results which are described above are highly dependent on the nutritional status of the tissue donors from whom the Northern and Western blots were prepared.
Chromosomal assignment
DNA samples from 18 different human/rodent cell hybrids were analyzed by Southern blotting using the human VLCAD cDNA probe. Following digestion with HindIII, two hybridizing bands were detected. This analysis shows that the human VLCAD gene is located on chromosome 17. A more detailed mapping using human/rodent cell hybrids harboring breakpoint chromosomes shows that the human VLCAD gene is located on the short arm of chromosome 17 between bands p11.2 and p11.13105.
Investigation of patients with defective dehydrogenation of long-chain acyl-CoA esters
Having established the necessary molecular genetic basis, we decided to search for the molecular defect in patients indicated to suffer from VLCAD deficiency. Four patients (600, 615, 8157 and 493) proven to be defective in dehydrogenation of palmitoylCoA by a modified electron transfer flavoprotein (ETF) based enzyme assay (24) , were chosen for molecular analysis. In all four patients measurements of enzyme activity by the method of Bertrand and coworkers (13) showed that the enzyme deficiency was localized to the membrane fraction of the mitochondria, consistent with a defect in VLCAD ( Table 1 ). The case histories of the four patients are given in the Materials and Methods section.
Northern blot analysis of total RNA from patient and control fibroblasts using the VLCAD probe ( Fig. 3) showed a single band of the expected size in the controls and in patients 600, 615 and 8157. In patient 493 there was no detectable band corresponding to VLCAD mRNA, although the integrity of the RNA was tested by hybridization with the β-actin probe (not shown). This indicates that the mutant VLCAD alleles in patient 493 result in severely reduced steady state amounts of VLCAD mRNA, thus explaining the loss of enzyme activity in this patient.
In order to search for mutations in VLCAD cDNA we amplified and sequenced a 2144 bp long fragment harboring the entire coding region and part of the 5′-and 3′-flanking sequences from fibroblast total RNA from a normal control and patients 600, 615 and 8157. In all three patients two or more positions with apparent heterozygosity for mutations were observed ( Table 2) . Except for the mutations listed in Table 2 the sequence of the 2144 bp PCR product from the three patients was identical to the normal VLCAD cDNA sequence. Unfortunately, no material was available from family members of any of the patients. Therefore, we cloned the amplified 2144 bp PCR products and sequenced several clones from each patient in order to establish whether the observed mutations are located in the same or separate chromosomes. This showed that in all three patients both alleles harbored at least one mutation, showing that patients 600, 615 and 8157 are compound heterozygotes. Patient 600 and patient 615 harbored three mutations each. In patient 600 the Gly401Asp and Leu562Ile mutations are located in the same allele and in patient 615 the Val243Ala and Val277Ala mutations are located in the same allele. 
The enzyme-activity (mean of three ± SD) was measured as dehydrogenation of palmitoyl-CoA in a membrane extract from skin fibroblasts using the ETF reduction assay (13). The nature and position of the mutations identified in the four investigated patients are listed. Moreover, the homologous residues in mature MCAD are listed.
Despite several attempts we were unable to amplify the 2144 bp fragment from patient 493. However, by PCR amplification of several cDNA preparations from patient 493 we were able to produce small amounts of two overlapping fragments of 1265 bp and 1372 bp, which together encompass the entire VLCAD coding region and parts of the 5′-and 3′-flanking untranslated regions. Sequence analysis of the two fragments showed apparent homozygosity for a 4 bp insertion of CAGA at position 1679 ( Table 2 ). The fact that the parents of this patient are first cousins suggests that he is homozygous for this mutation. It should, however, be noted that we were unable to completely sequence the two fragments. Therefore, the possibility of additional mutations in the VLCAD cDNA of patient 493 exists. Moreover, the observed 4 bp insertion mutation might be caused by a splicing abnormality.
Western blot analysis of patients 600, 615 and 8157
Western blot analysis for VLCAD protein was performed on fibroblasts from patients 600, 615 and 8157 and a control (Fig. 4) . A band with a size corresponding to mature VLCAD protein was observed in controls, but this band was barely detectable in patient samples. This shows that the mutant cDNA sequences identified in patients 600, 615 and 8157 all result in production of severely reduced steady-state amounts of VLCAD protein. Unfortunately there was no material available for analysis from patient 493.
DISCUSSION
The present study provides an illustrative example of how the sequence of a human disease gene can rapidly be identified by the powerful new PCR based techniques, when sequence information from expressed sequence tags (EST) isolated from human cDNA libraries are combined with sequence information on the gene in question from related species. Extensive sequence homology between a human EST (accession no. T08506) and rat VLCAD cDNA (21) allowed us to use a RACE based strategy to obtain the sequence of cDNAs encoding human VLCAD from placenta and fibroblasts. This enabled us to study the molecular genetic basis of VLCAD deficiency in four unrelated patients, to investigate the tissue specific expression of VLCAD, and to perform a chromosomal assignment of the VLCAD gene.
Homology of human VLCAD with other human ACD enzymes and human acyl-CoA oxidase: structure/function predictions Alignment of the mature human VLCAD protein sequence with that of other human acyl-CoA dehydrogenases (Fig. 5) showed that a region from glutamate-56 to lysine-440 of the mature human VLCAD displays a high degree of homology with the other enzymes of this family: 26, 29, 30, 31, 32 and 33% identity with LCAD, GCD, MCAD, IVD, SBCAD and SCAD respectively. Therefore, there can be no doubt that this region of human VLCAD harbors the ACD domain, and that human VLCAD is also a member of the ACD gene family (11) . It is remarkable that VLCAD shares the lowest degree of sequence similarity with LCAD despite the fact that the two enzymes act upon the most similar substrates. Moreover, the active site glutamate-261 of LCAD (25) is not conserved in human VLCAD (Fig. 5) . In contrast glutamate-422 of human VLCAD (Fig. 5) is homologous with the active site glutamate-376 of MCAD (26, 27) indicating that the active site of human VLCAD is similar to that of MCAD. Several other amino acids with a role in enzyme function known in MCAD are conserved in human VLCAD. Among them are tryptophan-209 (position 166 in MCAD), which is believed to play a role in electron transfer from the FAD bound to MCAD to ETF, and threonine-177 (position 136 in MCAD) and serine-183 (position 142 in MCAD) which form hydrogen bonds to the flavin moiety of MCAD (27) (Fig. 5) .
From the crystal structure of MCAD (27) it is known that the tetrameric enzyme may be regarded as a dimer of two dimers. Several of the residues which are important for the interaction of the two subunits within the dimer and some residues important for the dimer-dimer interaction have been identified based on the crystal structure (27) and functional studies (28) . Arginine-281 and glutamine-349 form hydrogen bonds with the pyrophosphate moiety of FAD of the neighboring subunit of the MCAD dimer, while glycine-353 form hydrogen bonds with the ribose moiety of FAD of the neighboring subunit. All these residues (arginine-326, glutamine-395 and glycine-399) are conserved in human VLCAD (Fig. 5) , indicating that the region involved in FAD binding and dimerization in VLCAD is very similar to that in MCAD. Aspartate-300 and arginine-383 form an important salt bridge between the two dimers of the tetrameric MCAD enzyme (28) . Although arginine-383 is conserved, aspartate-300 is replaced with arginine in VLCAD (Fig. 5) , excluding salt bridge formation. This is in perfect agreement with the fact that the functional VLCAD enzyme is not a tetramer but only a dimer (2, 3) .
In addition to the part of VLCAD which is homologous to the other ACD enzymes, VLCAD has a carboxyterminal extension of about 170-180 amino acids. The role of this extra polypeptide stretch is unclear, but it could be speculated whether it plays a role in membrane association of the enzyme. Aoyama and coworkers (20) noted a repetitive pattern of hydrophobic/hydrophilic regions in the carboxyterminal extension of rat VLCAD excluding the possibility that this part of the protein functions as a hydrophobic anchor in the mitochondrial membrane. We have observed a similar pattern in the human protein corroborating this notion.
The acyl-CoA oxidases, which catalyze the initial dehydrogenation reaction in the peroxisomal fatty acid oxidation and exhibit amino acid sequence similarities with the ACD enzymes, have been suggested to constitute a gene-super-family together with the ACD enzymes (29) . Interestingly the acyl-CoA oxidases are homo-dimers like VLCAD and harbor a similar carboxyterminal extension as VLCAD (30) . Comparison of the amino acids from position 56 to position 440 of human VLCAD ('ACD domain') with the amino acids from position 23 to position 439 of human acyl-CoA oxidase (ACOX) (30) show that they exhibit significant homology with 18% identical residues (Fig. 5) .
Comparison of the amino acids located in the carboxyterminal extension of the two enzymes (pos. 441 of the carboxyl end of human VLCAD and pos. 445 to the carboxyl end of human ACOX) shows 19% identical residues (Fig. 5) . This may suggest that the functional role of the carboxyterminal extensions of the two enzymes is the same. Tanaka and Indo (29) have previously discussed whether the primordial ACD/ACOX gene contained the carboxyterminal extension or if it was later conjugated during the evolution of the VLCAD/ACOX enzymes. Interestingly an alignment of the human ACOX protein sequence with that of other ACOX enzymes from rat and yeast strains [accession no. P07872, P34355, A29441, A27331, A25123, B25123, P13711 (PIR or Swissprot data bases)] revealed that the carboxyterminal extension is not as conserved as the remaining portion of these enzymes (results not shown), although the biochemical function of the carboxyterminal extension is most likely the same. Taking this into consideration, it is remarkable that a rather high sequence homology between the carboxyterminal extensions of VLCAD and ACOX can be observed. This could speak in favor of the evolutionary model suggested by Tanaka and Indo (29) , namely that the primordial enzyme was an ACD like enzyme without the carboxyterminal extension, and that this domain was later acquired by the ancestral VLCAD/ACOX enzyme. No conclusive argument for this sequence of events can be drawn at present, but future studies aimed at elucidating the functional role of the carboxyterminal extension domain of VLCAD and ACOX will perhaps prove helpful in determining the molecular evolution of this gene super-family.
The molecular defect in patients with VLCAD deficiency
Our analysis of VLCAD mRNA and VLCAD cDNA from four patients, suspected to suffer from VLCAD deficiency, showed that they all had mutations in the protein coding sequence of their VLCAD alleles (Table 2) . This is consistent with the expected autosomal recessive inheritance of this disease. Together with the observation of severely decreased amounts of VLCAD immunoreactive material in the three patients, and the observed severely decreased amounts of VLCAD mRNA in the fourth patient, this verifies that the defective palmitoyl-CoA oxidation can be ascribed to defects in VLCAD. All the identified mutations, except the 4 bp insertion and the Leu562Ile variation (see below), are located within the ACD domain of VLCAD. Therefore, comparison with the X-ray structure of MCAD, and comparison with amino acids at the homologous positions in the other ACD enzymes, may aid in explaining the molecular consequences of the identified mutations, and shed light on the molecular background of the severely reduced steady state amounts of mutant VLCAD protein observed in patient cells. Glycine-401 is together with glycine-399 in VLCAD located in one of the two highly conserved gly-gly-x-gly motifs (Fig. 5) . Apart from the interaction (mentioned above) of glycine-353 (glycine-399 in VLCAD) with FAD of the other subunit, the gly-gly-x-gly motif has been suggested to be of importance for the polypeptide chain to accommodate the nucleotide portion of the FAD (9) . As mentioned previously arginine-326 also interacts with FAD in the other subunit. Thus the drastic substitution of asparagine for glycine-401 in one of the VLCAD alleles of patient 600 and the mutation of arginine-326 to cysteine in one of the VLCAD alleles of patient 615 (Fig. 5) , could be speculated to disturb FAD-binding and subunit dimerization in the mutant VLCAD. A study by Saijo and Tanaka (31) has suggested that lack of FAD results in folding incompetence of MCAD leading to decreased amounts of enzyme. It is therefore likely that mutation of arginine-326 and glycine-401 result in impaired folding of the mutant VLCAD protein.
The residues in the mature MCAD monomer corresponding to the mutated VLCAD amino acid residues threonine-220, alanine-241, valine-243, and valine-277 present in patients 8157 and 615 are all situated in the lower part of the β-sheet domain with the side-chains embedded inside this densely packed part of the enzyme (27) . We believe that even small changes in the side-chains would affect the folding of the β-sheet domain.
The deleted glutamic acid-341 observed in one of the alleles of patient 600 corresponds to phenylalanine-296 in helix H of MCAD. Three different disease causing mutations (M301T, K304E and S311R) found in patients with MCAD deficiency (32) are located close to phenylalanine-296, indicating the importance of this region. Deletion of glutamic acid-341 would shorten and twist the helix. This would affect the structure of the VLCAD protein, perhaps influencing the folding process. In other genes in-frame deletions of one or more amino acid have, to the best of our knowledge, always been associated with disease (33) (34) (35) (36) (37) .
In conclusion, all the mutations located in the ACD domain of the three patients 600, 615 and 8157 can be predicted to affect the enzyme structure, and it is likely that they cause impaired folding of the mutant VLCAD protein, leading to degradation of the unstable folding intermediates. This may explain the severely decreased amounts of VLCAD protein observed in the three patients. Direct evidence for this suggested molecular defect mechanism can, however, not be provided until in vitro expression experiments with mutant VLCAD cDNA have been carried out. Anyway, there can be no doubt that the lack of functional VLCAD protein, most probably caused by the identified mutations, is causative for the disease in these patients. In line with this is the observation that molecular investigation of several disease causing mutations in MCAD have revealed that they all affect the folding process, resulting in decreased steady state amounts of MCAD protein (28, 32, (38) (39) (40) . Moreover, mutations in SCAD and IVD show a similar pattern (8, 41, 42) . Thus, the molecular defect mechanism may be similar in the ACD deficiencies.
In patient 493 the identified 4 bp insertion would lead to truncation of the VLCAD protein by 94 amino acids. Anyway, it is well known that mutations causing premature termination of translation usually result in severely reduced levels of mutant mRNA, and that this in turn leads to a reduction in the amounts of protein severe enough to cause disease (43) (44) (45) . Thus, the reduced amounts of VLCAD mRNA observed in patient 493 is probably by itself disease-causing, irrespective of the nature of the putative mutant protein. Because the conservative Leu562Ile substitution observed in patient 600 is located in the same allele as the drastic Gly401Asp mutation, it may be a neutral variation. But it can not be excluded that it has an effect, perhaps adding to the effect of the Gly401Asp mutation.
Tissue specific distribution of VLCAD and clinical symptoms in patients
In addition to the general clinical symptoms of fasting induced non-ketotic hypoglycemia with dicarboxylic aciduria usually observed in patients with defective palmitoyl-CoA dehydrogenation (3, 16, 46) , cardiac, skeletal muscle and liver symptoms are also frequently observed in this patient group (3, 19, 46) . Our observation that VLCAD mRNA and protein are most abundant in heart, skeletal muscle and liver corresponds well with these clinical symptoms. Furthermore, our results are consistent with the recent observation by Aoyama and coworkers, that VLCAD accounts for the vast majority of palmitoyl-CoA dehydrogenation activity in heart, liver, skeletal muscle and fibroblasts (3) .
Our data also show that LCAD has a different tissue specific distribution than VLCAD and MCAD. This observation may suggest that LCAD plays a different biochemical role than the other acyl-CoA dehydrogenases, and that the clinical presentation of LCAD deficiency may be completely different from that of VLCAD deficiency and the other disorders of fatty acid oxidation. This issue clearly needs further investigation. In MCAD deficiency, cardiac and muscle symptoms are not typical. Despite this, we observed a tissue specific distribution pattern of MCAD mRNA and protein which was almost identical to that observed for VLCAD. An explanation for this could be that the heart and muscle symptoms observed in patients with VLCAD deficiency are not primarily caused by the energy deficiency resulting from the enzymatic defect, but rather due to the toxic effects of accumulating long-chain metabolites. Patients with VLCAD deficiency accumulate C14:1 and C16 monounsaturated long-chain acyl-carnitines in the plasma (47) , and long-chain acyl-carnitines are known to be toxic, causing myocardial injury and rhythm disturbances (48) .
It is interesting to note that cardiomyopathy was only observed in one of our patients (patient 600), as compared to the seven VLCAD deficient patients recently reported (3), all of whom showed severe cardiac and muscle involvement, with hypertrophic cardiomyopathy present in four. However, in the dead siblings of three of our four index patients cardiac involvement had been noted. This adds to the notion that cardiac involvement is a frequent clinical sign of VLCAD deficiency. Furthermore, the fact that different clinical phenotypes can be observed in patients with the disease, even within the same families, illustrates that the clinical manifestations of VLCAD deficiency are heterogenous.
Data from the present study, as well as data from others (3, 16, 46) show that patients suffering from VLCAD deficiency generally present very early, and that an initial presentation in the first days of life is common. Because the clinical course may be severe and treatment with diet and avoidance of fasting seems promising, an early and reliable diagnosis is very important. The traditional diagnostic methods (3, 12, 13, 49) are technically demanding and are available in few laboratories. Therefore, the availability of the human VLCAD cDNA sequence may provide the basis for a significant addition to the existing diagnostic methods. Moreover, it allows analyzing of family members for mutation carrier status, which is not feasible with the existing diagnostic methods.
Aoyama and coworkers have recently reported the identification of two unrelated patients who were both homozygous for a 105 bp deletion in the VLCAD cDNA sequence (20) . The 105 bp deletion was not present in any of our patients, all of whom had different mutations. This, together with the noted heterogeneity in size and stability of the mutant VLCAD proteins from seven patients investigated by pulse-chase experiments (3), indicates that the mutational spectrum in VLCAD deficiency consists of many different mutations. This implies that a DNA based diagnosis for this disease may not be as straight-forward as previously observed for the majority of patients with MCAD deficiency (50, 51) .
Chromosomal localization of the human VLCAD gene
Because VLCAD could potentially be a candidate gene for heart disease we investigated the possibility that the VLCAD gene maps to one of the regions known to harbor candidate genes for heart disease. Our results showed that the human VLCAD gene is located on the short arm of chromosome 17 between bands p11.2 and p11.13105. To the best of our knowledge no candidate genes for heart disease have been mapped to this region of chromosome 17.
Previously all the human ACD genes and the human ACOX gene have been localized to different chromosomes (9, (52) (53) (54) (55) (56) . It is therefore interesting to note that the VLCAD and ACOX genes are both located on chromosome 17, especially in relation to the fact that gene duplication may have played a role in the evolution of the ACD/ACOX gene-super-family (29) and the fact that VLCAD and ACOX may be evolutionarily close (see above).
MATERIALS AND METHODS
Characterization of human very-long-chain acyl-CoA dehydrogenase cDNAs
Adaptor ligated double stranded cDNAs from human placenta and human fibroblasts were prepared using a Marathon cDNA amplification kit from Clonetech (Palo Alto, CA). The TFastA program of the GCG sequence analysis package (University of Wisconsin Genetics Computer Group) was used to search the EMBL/GeneBank databases for sequences with homology to rat VLCAD cDNA (21) . In this way we identified an expressed sequence tag isolated from a human fetal brain cDNA library (accession no. T08506) which showed extensive sequence homology. Two human VLCAD cDNA specific primers, p716S and p845AS (Table 3) were designed based on this sequence. 5′-RACE-PCR was performed using the adaptor specific primer, AP1 (Table 3) , and the p845AS primer. 3′-RACE-PCR was performed using AP1, and the p716S primer. The PCRs were carried out essentially as recommended (Marathon cDNA amplification kit, Clonetech, Palo Alto, CA) with double stranded adaptor ligated cDNAs as template. In both 5′-and 3′-RACE-PCR only a single band was observed. This band was gel purified and cloned in a pCRII vector (Invitrogen, San Diego, CA). Clones were sequenced with a combination of VLCAD cDNA specific primers (Table 3 ) and vector specific primers (Sp6 and M13-forward primer). Five clones harboring 5′-RACE-PCR products and three clones harboring 3′-RACE-PCR products were sequenced. PCR products produced with a 5′-biotinylated AP-1 primer were subjected to solid-phase direct sequencing as described below. The nucleotides which introduce artificial HincII (p-6S) and ClaI (p1329AS) are underlined, with the mismatching nucleotides in bold face.
Patients
Patient 600 is the last of four children born to healthy unrelated parents. The first child presented during the first 24 h of life and at 2½ months of age with tachypnea, lethargy, hypoglycemia and dicarboxylic aciduria with normal acyl-glycines. He died during the second episode following cardiorespiratory arrest. Autopsy revealed biventricular hypertrophy of the heart and hepatomegaly. The index patient presented at 29 h of age, at 5 days of age and at 4 months of age with tachypnea, lethargy, hypotonia and hypoglycemia which was corrected by intravenous glucose. Only two days following the third episode the fourth episode occurred. At this point hepatomegaly and severe cardiomyopathy were documented. Her diet was changed to increase the proportion of medium chain triglycerides (MCT). At 7 months of age, she was growing and developing normally with a normal heart exam, echocardiogram, and liver size.
Patient 615 presented at 26 h of age with an episode of tachypnea, hypoglycemia and dicarboxylic aciduria with normal acyl-glycines, which was corrected by intravenous glucose. By 6 days of life, plasma acyl-carnitine analysis indicated VLCAD deficiency, and she was put on a high carbohydrate diet with an increased proportion of MCT, along with carnitine supplementation. She is now 20 months old and she has done well clinically since with no signs of cardiac manifestations. She had five siblings, one of which, a male, died at 36 h of age with bradycardia with a 2:1 atrioventricular block. Autopsy revealed fatty infiltrations of the liver and the heart was enlarged and dilated.
Patient 8157's case history has been published previously (13, 58) .
Patient 493 presented at 25 and 26 months of age with drowsiness, hypothermia and hypotonia after an overnight fast. He had dicarboxylic aciduria with ketosis and severe hypocarnitinemia. The condition was rapidly corrected by glucose infusion. Examination showed no cardiac symptoms or cardiomyopathy. Previously a sibling died at 6 months of age of cardiac failure without diagnosis. The parents are first cousins. The patient is now 3½ years old and is in good clinical condition under carnitine supplementation and dietary advice to avoid fasting.
Investigation of blood samples from each of the four index patients by tandem mass spectrometry (49) showed C14:1-and C16-acyl-carnitine elevation in plasma, indicating a defect in VLCAD. In addition, the enzyme defect in patients 600, 615 and 8157 was also indicated by the in vitro probe assay (47) .
Enzyme assay
Acyl-CoA dehydrogenase activity in cultured skin fibroblasts from each of the four index patients was assayed as described previously (24) , using a modified version of the ETF assay (59) . The enzyme activity of matrix and membrane fractions with palmitoyl-CoA as substrate were assayed in triplicate as described previously (13) .
RNA extraction and Northern blot
Two nylon filters containing similar amounts of poly-(A) + mRNA from different human tissues (Clonetech, Palo Alto, CA) were used for Northern hybridization. To ascertain that the observed results are representative, the two filters were obtained from different batches. Both filters were hybridized with probes for VLCAD, LCAD and MCAD but in different order. The integrity of the filters was tested by hybridization to a β-actin probe. The filters were hybridized and washed as recommended by the manufacturer.
Total RNA was prepared from frozen patient fibroblasts using a RNeasy kit (Qiagen, Hilden, Germany). Northern blot analysis of 10 µg total RNA from patient and control fibroblasts was performed as described previously (60) using the VLCAD probe and the β-actin probe.
The probes spanning the entire human VLCAD cDNA, the entire LCAD coding region and the entire MCAD coding region were α-[ 32 P]-labeled by random hexamer labeling (61) . The MCAD probe has previously been described (60) . In order to obtain a probe recognizing human LCAD mRNA a 1335 bp fragment was generated by PCR amplification of cDNA from human placenta using the primers p-6S and p1329AS (Table 3 ). The PCR product was cloned into the pCRII vector (Invitrogen, San Diego, CA), and the identity of the insert was verified by sequence analysis. Prior to labeling, the entire LCAD cDNA insert was cut out of the vector with HincII and ClaI, and gel purified.
Sequence analysis of patients
From patients and a control person 1 µg fibroblast total RNA was used for first strand cDNA synthesis using a first strand cDNA synthesis kit (Clontech, Palo Alto, CA). From control placenta 1 µg of poly-(A) + mRNA was used instead. Several cDNAs were synthesized from each of the four patients (600, 615, 8157 and 493), control fibroblasts, and control placenta. PCR amplification of a 2144 bp long fragment covering the entire protein coding region and part of the flanking sequences was performed using the two primers: p-57S and p2087AS (Table 3 ). In addition two shorter fragments of the VLCAD cDNA were amplified using the primer pairs p-42S/p1222AS and p716S/p2087AS (Table 3) . PCR with p-42S and p1222AS produce a 1265 bp long fragment, and PCR with p716S and p2087AS produce a 1372 bp long fragment. The PCRs were carried out under standard conditions with first strand cDNA as template. The PCR product for sequencing the sense-strand was produced with a non-biotinylated sense primer and a 5′-biotinylated antisense primer, and the product to be used for sequencing in the antisense direction was produced with a 5′-biotinylated sense primer and a non-biotinylated antisense primer. Quantities of 25-75 µl of the PCR products were captured from the reaction mix with streptavidin conjugated magnetic beads and prepared for sequencing as recommended by the manufacturer (Dynal, Skøyen, Norway). Bidirectional solid-phase dideoxy-sequencing employing primers listed in Table 3 was performed using a prism T7 kit (Perkin Elmer Cetus, Norwark, CA) and a semiautomated ABI 373A sequencer (Applied Biosystems). The 2144 bp product was also produced with non-biotinylated p-57S and p2087AS primers and cloned into a pCRII vector (Invitrogen, San Diego, CA). Several clones from each of the patients 600, 615 and 8157 were isolated and sequenced.
Establishment of a polyclonal antibody directed towards human VLCAD antigen
A cDNA fragment encoding amino acids 239 to 350 of the human VLCAD protein was fused to maltose binding protein in the pMal-c2 vector (New England Biolabs, Beverly, MA) and expressed in E.coli. The fusion protein was purified using amylose resin (New England Biolabs, Beverly, MA) followed by preparative SDS gel electrophoresis (ProSieve, FMC BioProducts, Rockland, ME) and used to raise a polyclonal antibody in rabbits.
Western blotting
Two PVDF membranes containing similar amounts of total cellular protein from different human tissues (MTW blot, Clonetech, Palo Alto, CA) were used for Western blot analysis as described by the manufacturer. The blots were stained using the Western Exposure Chemiluminescent Detection system from Clontech (Palo Alto, CA). Both membranes were probed in different order with an antibody previously shown to be monospecific for human and rat LCAD (17), our VLCAD antibody and an rabbit anti-porcine MCAD antibody (26) . Frozen patient fibroblast cell pellets were disrupted by boiling in sample buffer and subjected to SDS-PAGE followed by Western blotting as previously described (38) . Approximately 30 µg total protein of the supernatant fraction was loaded in each lane of the gel.
Incubation with VLCAD antibody and staining was performed as described above.
Cell hybrids
Cell hybrid DNA from the NIGMS Human/Rodent Somatic Cell Hybrid Mapping Panel #1 and chromosome 17 Regional Mapping Panel were obtained from NIGMS Human Genetic Mutant Cell Repository (Camden, NJ). Restriction enzyme digestion of hybrid cell DNA, Southern transfer, and filter hybridization were carried out as described previously (62) using the VLCAD cDNA probe.
